A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure-Reference-Cited by-同舟云学术

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

Published:2013-07 Issue:1 Volume:42 Page:42-47
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Marcelin Anne-Geneviève,Delaugerre Constance,Beaudoux Céline,Descamps Diane,Morand-Joubert Laurence,Amiel Corinne,Schneider Veronique,Ferre Virginie,Izopet Jacques,Si-Mohamed Ali,Maillard Anne,Henquell Cécile,Desbois Delphine,Lazrek Mouna,Signori-Schmuck Anne,Rogez Sylvie,Yerly Sabine,Trabaud Mary-Anne,Plantier Jean-Christophe,Fourati Slim,Houssaini Allal,Masquelier Bernard,Calvez Vincent,Flandre Philippe

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference19 articles.

1. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection;Summa;J Med Chem,2008

2. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009

3. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

4. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study;Markowitz;J Acquir Immune Defic Syndr,2007

5. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 phase III trials;Steigbigel;Clin Infect Dis,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil;International Journal of STD & AIDS;2020-07-23

2. Weighted Kaplan‐Meier estimators motivating to estimate HIV‐1 RNA reduction censored by a limit of detection;Statistics in Medicine;2020-01-24

3. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors;International Journal of Antimicrobial Agents;2019-11

4. Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals;Journal of Medical Virology;2019-08-20

5. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing;Journal of Antimicrobial Chemotherapy;2018-06-04